Vaginitis and VulvovaginitisNCT04735705
Clinical Investigation To Evaluate Cerviron Ovules® in Symptomatic Vaginitis
A study testing Cerviron in people with Vaginitis and Vulvovaginitis, run by Perfect Care Distribution at 2 sites in Romania.
Trial summary
CYRON is a Prospective, Open-Label, Pilot, Multicentric Clinical Investigation to Evaluate the Performance and Safety of Cerviron Ovules® in the Local Treatment of Non-Specific or Endogenous, Symptomatic Vaginitis. Read more about this study
- Who is it for?
- Ages 18 to 65 years, women only
- Conditions the study is for
- Vaginitis and Vulvovaginitis
- What is being tested?
- Cerviron
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 50 participants
- Where
- 2 sitesRomania
- Study dates
- 1 Apr 2021to 9 Sep 2021
- Phase
- Interventional
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adult females, aged 18 years to 65 years;
- Subjects presenting two or more vaginal symptoms such as leucorrhoea, pruritus, burning sensation, erythema, pain, odour, dysuria, or dyspareunia;
- Subjects with a diagnosis of either non-infectious vaginitis, or endogenous, symptomatic infection;
- Negative for Gardnerella vaginalis, Candida albicans, Trichomonas vaginalis;
- Subjects willing to provide signed informed consent to clinical investigation participation.
Who cannot join
- Subjects in menstrual period or suffering from menorrhagia;
- Colpectomy;
- Subjects with undiagnosed abnormal genital bleeding;
- Subject with vulvar, vaginal or cervical cancer;
- Known, active sexually transmitted infection (STI) in partner, as per anamnesis;
- Subjects with HIV or other immunodeficiency;
Show all 13Show fewer
- Subjects with any pathology of the female reproductive organs;
- Known allergy or hypersensitivity to the medical device ingredients;
- Use of spermicides;
- Use of diaphragm;
- Concomitant topical or systemic anti-infective treatment;
- Unable to comply with visit procedures;
- Subjects included in other clinical investigations;
Trial locations and contacts
2 sites in 1 country.
Romania2 sites
Institutul National pentru Sanatatea Mamei si Copilului (INSMC) "Alessandrescu - Rusescu"
Bucharest
Spitalul Clinic Județean de Urgență "Pius Brinzeu"
Timișoara, Timiș County
About this study
Official title: A Prospective, Open-Label, Pilot, Multicentric Clinical Investigation to Evaluate the Performance and Safety of Cerviron Ovules® in the Local Treatment of Non-Specific or Endogenous, Symptomatic Vaginitis
CYRON is a Prospective, Open-Label, Pilot, Multicentric Clinical Investigation to Evaluate the Performance and Safety of Cerviron Ovules® in the Local Treatment of Non-Specific or Endogenous, Symptomatic Vaginitis. The primary objective is to assess the therapeutic performance and tolerability of Cerviron® Ovules in patients with symptomatic, non-specific, non-infectious vaginitis, and endogenous symptomatic infections.
The secondary objective of this clinical investigation is the assessment of performance of the medical device by several additionally clinical outcomes (vaginal discharge, vaginal pH, microscopic characteristics of inflammatory cells and characteristics of vaginal microflora).
Participants will also evaluate the degree of satisfaction related to the use of the medical device.
Read the detailed description
Vaginitis is the general term characterizing a spectrum of disorders of the vagina caused by infection, inflammation, or changes in the normal vaginal flora. Symptoms include abnormal vaginal discharge, odour, pruritus, pain, dysuria and/or discomfort. Moreover, vaginitis is responsible for the most common problems in clinical medicine, and it is the reason cited most often for visits to obstetricians and gynecologists. In the past years, the problem of vaginitis has all too often been ignored by the medical community or regarded merely as a minor annoyance to women. According to Gardner, "Vaginitis must cause more unhappiness on earth than any other gynecologic disease. In addition to the many physical and emotional problems associated with vaginitis, the economic loss involved is of astronomic proportions." The most common causes of vaginitis are bacterial vaginosis, vulvovaginal candidiasis, and trichomoniasis. Bacterial Vaginosis is the cause in 40% to 50% of cases in which a cause is identified, with vulvovaginal candidiasis accounting for 20% to 25% and trichomoniasis for 15% to 20% of cases. The standard of care currently is based on anti-infectious therapy. With the availability of complementary and alternative therapies and over-the-counter medications for vaginitis, many symptomatic women seek these products before or in addition to an evaluation by a medical provider. However, recurrence of vaginosis is frequent, and can include four or more episodes in one year.
Non-infectious cases, including atrophic, irritant, and inflammatory vaginitis, are less common and account for 5% to 10% of vaginitis cases. Obtaining a medical history alone has been shown to be insufficient for accurate diagnosis of vaginitis and can lead to the inappropriate administration of medication. Therefore, a careful history, examination, and laboratory testing to determine the etiology of vaginal symptoms are needed. Information on sexual behaviors and practices, gender of sex partners, menses, vaginal hygiene practices (e.g., douching), and self-treatment with medications should be collected.
Other causes of vaginitis There is no cause of vagini¬tis identified in up to 30% of women. These women may have a range of conditions, includ¬ing irritant or allergic vaginitis, atrophic vaginitis, or physiologic discharge. The presence of objective signs of vulvar inflammation in the absence of vaginal pathogens after laboratory testing suggests the possibility of mechanical, chemical, allergic, or other non-infectious causes of vulvovaginal signs or symptoms.
Inflammatory vagi¬nitis is an uncommon condition characterized by purulent vaginal discharge, burning, and dyspa¬reunia, and should be considered in patients with these symptoms if no infectious cause is found. Inflammatory vaginitis is associated with low estrogen levels, such as in menopausal or perimenopausal women.
Desquamative inflammatory vaginitis is a chronic inflammatory process involving both vagina and vestibule, occurring almost exclusively in white women, that responds well to topical anti-inflammatory therapy. Long-term maintenance therapy is frequently required.
Irritant/allergic vaginitis is characterized by symptoms such as burning and soreness and signs such as vulvar erythema.
Atrophic vaginitis is an uncommon condition that occurs as a consequence of estrogen deficiency and is characterized by symptoms such as thin, clear discharge, vaginal dryness, dyspareunia, itching. An examination of the vulva can indicate inflammation and thin and friable vaginal mucosa. Risk factors contributing to atrophic vaginitis are menopause, lactation, oophorectomy, radiation therapy, chemotherapy, immunologic disorders, premature ovarian failure, endocrine disorders, and antioestrogen medications.
Aerobic vaginitis is a distinct vaginal condition, requiring different clinical management and with distinct clinical risks. (7) Aerobic vaginitis is defined by disruption in Lactobacillus dominance but is accompanied by more extreme inflammatory changes than BV and the presence of mainly aerobic enteric commensals or pathogens, including Group B Streptococcus (S. agalactiae), Enterococcus faecalis, Escherichia coli, and S. aureus. Streptococcus agalactiae (group B Streptococcus, GBS) vaginal pathogenicity is not uniformly acknowledged throughout the literature. GBS virulence for vagina was recognized in the past, as the organism has been observed to potentially cause local inflammation and discharge, as well as lactobacilli rarefaction.
Cytolitytic vaginosis is another condition which has been recently described as an entity distinct from either normal flora or bacterial vaginosis. This condition, also called Doderlein's vaginitis, has numerous, active lactobacilli damaging epithelial cells because of extreme acidity and low pH. The bare nuclei and cellular debris that are seen during microscopy, should not be mistaken for leucocytes and cocci.
Cerviron ovules® is a class IIb medical device indicated as adjuvant in the treatment of acute and chronic vulvovaginitis of mechanical etiology, caused by changes of vaginal pH and changes of the vaginal flora. It is also used in cervical lesions of mechanical origin as it favors the healing and re-epithelialization processes and reduces the proliferation of endogenous pathogens.
This is the first clinical investigation on human subjects with this medical device, in which 50 patients will be enlisted, and which will take place in two research centres in Romania.
- Conditions
- Vaginitis and Vulvovaginitis
- Being tested
- Cerviron
- Keywords
- Vaginitis, vaginal discharge, vaginal pH, vaginal microflora
- Medical subject headings
- Vaginitis, Vulvovaginitis, Vaginal Discharge
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CervironDevice
Cerviron ovules ® is a class IIb medical device indicated as adjuvant in the treatment of acute and chronic vulvovaginitis of mechanical etiology, caused by changes of vaginal pH and changes of the vaginal flora. It is also used in cervical lesions of mechanical origin as it favors the healing and re-epithelialization processes and reduces the proliferation of endogenous pathogens.
| Study group | Role | What they receive |
|---|---|---|
| Cerviron vaginal ovules | Experimental | Since Cerviron® has an innovative composition, we preferred an exploratory approach for the design of the present clinical investigation. Receives: Device: Cerviron |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of Participants With the Same Gynaecological Conditions at the End of Treatment Visit
Success is defined by resolution (return to patient's usual gynaecological conditions, i.e. before the episode which warranted inclusion in the study) OR substantial improvement of clinical signs of infectious vaginitis (i.e. abnormal vaginal discharge), and/or vaginal symptoms (vaginal burning and/or vaginal pain, and/or vaginal irritation and/or pruritus and/or odor). Failure is defined by persistence or worsening of symptoms and clinical signs or requirement of an alternative or specific treatment.
Measured: 3 months
Rate of Treatment-related Adverse Events in Subjects Participating in the Clinical Investigation
The safety of CERVIRON ® as measured by the rate of treatmentrelated adverse events, including serious adverse events (SAEs), in subjects participating in the clinical investigation.
Measured: 3 months
Secondary outcomes (5)
Number of Participants With Absent, Mild, Moderate or Abundant Vaginal Discharge at 1, 2 and 3 Months of Treatment
The vaginal discharge assessed by the investigator by using a score:
0=absent
- mild: insufficient for speculum collection
- moderate: sufficient for speculum collection
- abundant: visible at the introitus even before speculum introduction
- purulent, abnormal discharge: visible at the introitus even before speculum introduction
Measured: at 1, 2 and 3 months
Number of Participants With Change in Vaginal pH Values
Determination of pH values compared to its normal values (3.8 - 4.5)
Measured: at 1, 2 and 3 months
Number of Participants With Change in Vaginal Microflora and Lactobacilli Count
The change in Lactobacillus species as shown by microscopy
Measured: 3 months
Number of Participants With Change in Vaginal Inflammation
The change in inflammatory and parabasal cells by microscopy
Measured: 3 months
Results in Patient Satisfaction's Scale (Likert Scale)
The degree of satisfaction when using the medical device will be assessed using a five-point Likert Scale. The degree of satisfaction when using the medical device was assessed using a five-point Likert Scale, as very satisfied, satisfied, neutral, unsatisfied, and very unsatisfied.
Measured: 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Feb 2021
- Study start1 Apr 2021
- Primary completion9 Sep 2021
- Study completion9 Sep 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Vaginitis and VulvovaginitisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 50 participants (actual)
Sponsor and investigators
- Lead sponsor
- Perfect Care Distribution
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- MDX Research
- Responsible party
- Sponsor
- Investigators
- Ramona Petrita, CSO, Study director, MDX Research
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04735705
- Sponsor's protocol ID
- CYRON/01/2021
- Status last verified
- Feb 2023
- First submitted
- 29 Jan 2021
- Last updated
- 22 Nov 2023
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Toader DO, Olaru RA, Iliescu DG, Petrita R, Calancea FL, Petre I. Clinical Performance and Safety of Vaginal Ovules in the Local Treatment of Nonspecific Vaginitis: A National, Multicentric Clinical Investigation. Clin Ther. 2023 Sep;45(9):873-880. doi: 10.1016/j.clinthera.2023.06.023. Epub 2023 Jul 18.
PubMed 37474354
Study at a glance
From the registry record, last updated by the sponsor on 22 Nov 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Prospective, Open-Label, Pilot, Multicentric Clinical Investigation to Evaluate the Performance and Safety of Cerviron Ovules® in the Local Treatment of Non-Specific or Endogenous, Symptomatic Vaginitis
- ClinicalTrials.gov ID
- NCT04735705
- Acronym / sponsor ID
- CYRON/01/2021
- Conditions
- Vaginitis and Vulvovaginitis
- Keywords
- Vaginitis, vaginal discharge, vaginal pH, vaginal microflora
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 50 participants (actual)
- Lead sponsor
- Perfect Care DistributionIndustry (pharma, biotech, devices)
- Collaborators
- MDX Research
- Study start
- 1 Apr 2021 (actual)
- Primary completion
- 9 Sep 2021 (actual)
- Study completion
- 9 Sep 2021 (actual)
- First posted
- 3 Feb 2021 (actual)
- Results
- Posted 22 Nov 2023
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
CYRON is a Prospective, Open-Label, Pilot, Multicentric Clinical Investigation to Evaluate the Performance and Safety of Cerviron Ovules® in the Local Treatment of Non-Specific or Endogenous, Symptomatic Vaginitis. The primary objective is to assess the therapeutic performance and tolerability of Cerviron® Ovules in patients with symptomatic, non-specific, non-infectious vaginitis, and endogenous symptomatic infections.
The secondary objective of this clinical investigation is the assessment of performance of the medical device by several additionally clinical outcomes (vaginal discharge, vaginal pH, microscopic characteristics of inflammatory cells and characteristics of vaginal microflora).
Participants will also evaluate the degree of satisfaction related to the use of the medical device.
Detailed description
Vaginitis is the general term characterizing a spectrum of disorders of the vagina caused by infection, inflammation, or changes in the normal vaginal flora. Symptoms include abnormal vaginal discharge, odour, pruritus, pain, dysuria and/or discomfort. Moreover, vaginitis is responsible for the most common problems in clinical medicine, and it is the reason cited most often for visits to obstetricians and gynecologists. In the past years, the problem of vaginitis has all too often been ignored by the medical community or regarded merely as a minor annoyance to women. According to Gardner, "Vaginitis must cause more unhappiness on earth than any other gynecologic disease. In addition to the many physical and emotional problems associated with vaginitis, the economic loss involved is of astronomic proportions." The most common causes of vaginitis are bacterial vaginosis, vulvovaginal candidiasis, and trichomoniasis. Bacterial Vaginosis is the cause in 40% to 50% of cases in which a cause is identified, with vulvovaginal candidiasis accounting for 20% to 25% and trichomoniasis for 15% to 20% of cases. The standard of care currently is based on anti-infectious therapy. With the availability of complementary and alternative therapies and over-the-counter medications for vaginitis, many symptomatic women seek these products before or in addition to an evaluation by a medical provider. However, recurrence of vaginosis is frequent, and can include four or more episodes in one year.
Non-infectious cases, including atrophic, irritant, and inflammatory vaginitis, are less common and account for 5% to 10% of vaginitis cases. Obtaining a medical history alone has been shown to be insufficient for accurate diagnosis of vaginitis and can lead to the inappropriate administration of medication. Therefore, a careful history, examination, and laboratory testing to determine the etiology of vaginal symptoms are needed. Information on sexual behaviors and practices, gender of sex partners, menses, vaginal hygiene practices (e.g., douching), and self-treatment with medications should be collected.
Other causes of vaginitis There is no cause of vagini¬tis identified in up to 30% of women. These women may have a range of conditions, includ¬ing irritant or allergic vaginitis, atrophic vaginitis, or physiologic discharge. The presence of objective signs of vulvar inflammation in the absence of vaginal pathogens after laboratory testing suggests the possibility of mechanical, chemical, allergic, or other non-infectious causes of vulvovaginal signs or symptoms.
Inflammatory vagi¬nitis is an uncommon condition characterized by purulent vaginal discharge, burning, and dyspa¬reunia, and should be considered in patients with these symptoms if no infectious cause is found. Inflammatory vaginitis is associated with low estrogen levels, such as in menopausal or perimenopausal women.
Desquamative inflammatory vaginitis is a chronic inflammatory process involving both vagina and vestibule, occurring almost exclusively in white women, that responds well to topical anti-inflammatory therapy. Long-term maintenance therapy is frequently required.
Irritant/allergic vaginitis is characterized by symptoms such as burning and soreness and signs such as vulvar erythema.
Atrophic vaginitis is an uncommon condition that occurs as a consequence of estrogen deficiency and is characterized by symptoms such as thin, clear discharge, vaginal dryness, dyspareunia, itching. An examination of the vulva can indicate inflammation and thin and friable vaginal mucosa. Risk factors contributing to atrophic vaginitis are menopause, lactation, oophorectomy, radiation therapy, chemotherapy, immunologic disorders, premature ovarian failure, endocrine disorders, and antioestrogen medications.
Aerobic vaginitis is a distinct vaginal condition, requiring different clinical management and with distinct clinical risks. (7) Aerobic vaginitis is defined by disruption in Lactobacillus dominance but is accompanied by more extreme inflammatory changes than BV and the presence of mainly aerobic enteric commensals or pathogens, including Group B Streptococcus (S. agalactiae), Enterococcus faecalis, Escherichia coli, and S. aureus. Streptococcus agalactiae (group B Streptococcus, GBS) vaginal pathogenicity is not uniformly acknowledged throughout the literature. GBS virulence for vagina was recognized in the past, as the organism has been observed to potentially cause local inflammation and discharge, as well as lactobacilli rarefaction.
Cytolitytic vaginosis is another condition which has been recently described as an entity distinct from either normal flora or bacterial vaginosis. This condition, also called Doderlein's vaginitis, has numerous, active lactobacilli damaging epithelial cells because of extreme acidity and low pH. The bare nuclei and cellular debris that are seen during microscopy, should not be mistaken for leucocytes and cocci.
Cerviron ovules® is a class IIb medical device indicated as adjuvant in the treatment of acute and chronic vulvovaginitis of mechanical etiology, caused by changes of vaginal pH and changes of the vaginal flora. It is also used in cervical lesions of mechanical origin as it favors the healing and re-epithelialization processes and reduces the proliferation of endogenous pathogens.
This is the first clinical investigation on human subjects with this medical device, in which 50 patients will be enlisted, and which will take place in two research centres in Romania.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Cerviron vaginal ovules | Experimental | Device: CervironSince Cerviron® has an innovative composition, we preferred an exploratory approach for the design of the present clinical investigation. |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Adult females, aged 18 years to 65 years;
- Subjects presenting two or more vaginal symptoms such as leucorrhoea, pruritus, burning sensation, erythema, pain, odour, dysuria, or dyspareunia;
- Subjects with a diagnosis of either non-infectious vaginitis, or endogenous, symptomatic infection;
- Negative for Gardnerella vaginalis, Candida albicans, Trichomonas vaginalis;
- Subjects willing to provide signed informed consent to clinical investigation participation.
Key exclusion criteria (13 listed)
- Subjects in menstrual period or suffering from menorrhagia;
- Colpectomy;
- Subjects with undiagnosed abnormal genital bleeding;
- Subject with vulvar, vaginal or cervical cancer;
- Known, active sexually transmitted infection (STI) in partner, as per anamnesis;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| CervironCerviron ovules ® is a class IIb medical device indicated as adjuvant in the treatment of acute and chronic vulvovaginitis of mechanical etiology, caused by changes of vaginal pH and changes of the vaginal flora. It is also used in cervical lesions of mechanical origin as it favors the healing and re-epithelialization processes and reduces the proliferation of endogenous pathogens. | Device | Cerviron vaginal ovules |
Primary outcome
Number of Participants With the Same Gynaecological Conditions at the End of Treatment Visit
Time frame: 3 months
Success is defined by resolution (return to patient's usual gynaecological conditions, i.e. before the episode which warranted inclusion in the study) OR substantial improvement of clinical signs of infectious vaginitis (i.e. abnormal vaginal discharge), and/or vaginal symptoms (vaginal burning and/or vaginal pain, and/or vaginal irritation and/or pruritus and/or odor). Failure is defined by persistence or worsening of symptoms and clinical signs or requirement of an alternative or specific treatment.
Rate of Treatment-related Adverse Events in Subjects Participating in the Clinical Investigation
Time frame: 3 months
The safety of CERVIRON ® as measured by the rate of treatmentrelated adverse events, including serious adverse events (SAEs), in subjects participating in the clinical investigation.
5 secondary outcomes
Number of Participants With Absent, Mild, Moderate or Abundant Vaginal Discharge at 1, 2 and 3 Months of Treatment
Time frame: at 1, 2 and 3 months
Number of Participants With Change in Vaginal pH Values
Time frame: at 1, 2 and 3 months
Number of Participants With Change in Vaginal Microflora and Lactobacilli Count
Time frame: 3 months
Number of Participants With Change in Vaginal Inflammation
Time frame: 3 months
Results in Patient Satisfaction's Scale (Likert Scale)
Time frame: 3 months
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Nov 2023.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 37474354Toader DO, Olaru RA, Iliescu DG, Petrita R, Calancea FL, Petre I. Clinical Performance and Safety of Vaginal Ovules in the Local Treatment of Nonspecific Vaginitis: A National, Multicentric Clinical Investigation. Clin Ther. 2023 Sep;45(9):873-880. doi: 10.1016/j.clinthera.2023.06.023. Epub 2023 Jul 18.
- Individual participant dataSharing planned: No
Related trials for Vaginitis and Vulvovaginitis
Recruiting
Multi-Gyn FemiTotal for the Treatment and Prevention of Vulvovaginal Candidiasis Symptoms and Bacterial Vaginosis
Bacterial Vaginosis, Vaginal Candidiasis
Recruiting
F-GYN for Vaginal Dryness and Vulvovaginal Atrophy
Atrophic Vaginitis, Atrophic Vulvovaginitis
RecruitingObservational study
Safety of Pregnant Subjects Exposed to Ibrexafungerp Including Infant Outcomes
Vulvovaginitis, Candidal, Vulvovaginal Candidiasis
Active, not recruitingObservational study
Comparative Performance of a Vaginal Yeast Test
Vulvovaginal Candidiasis
Active, not recruitingObservational study
DeVEnIR: Defining Vulvovaginal Candidiasis - Elements of Infection and Remedy
Vulvovaginal Candidiasis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Ramona Petrita, CSO study director
MDX Research
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Cerviron in people with Vaginitis and Vulvovaginitis, run by Perfect Care Distribution at 2 sites in Romania.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 22 Nov 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Romania. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 22 Nov 2023). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of Participants With the Same Gynaecological Conditions at the End of Treatment Visit (time frame: 3 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04735705, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Nov 2023.